These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 16815311)

  • 1. Improving how we evaluate the toxicity of approved drugs.
    Reidenberg MM
    Clin Pharmacol Ther; 2006 Jul; 80(1):1-6. PubMed ID: 16815311
    [No Abstract]   [Full Text] [Related]  

  • 2. A proposal for radical changes in the drug-approval process.
    Wood AJ
    N Engl J Med; 2006 Aug; 355(6):618-23. PubMed ID: 16899784
    [No Abstract]   [Full Text] [Related]  

  • 3. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems.
    Glasser SP; Salas M; Delzell E
    J Clin Pharmacol; 2007 Sep; 47(9):1074-86. PubMed ID: 17766697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trials and public trust.
    Kennedy D
    Science; 2004 Dec; 306(5702):1649. PubMed ID: 15576574
    [No Abstract]   [Full Text] [Related]  

  • 5. How experimental drugs are tested in humans.
    Flieger K
    Pediatr Infect Dis J; 1989 Mar; 8(3):160-2. PubMed ID: 2710587
    [No Abstract]   [Full Text] [Related]  

  • 6. Beware of new drugs, study suggests.
    Levenson D
    Rep Med Guidel Outcomes Res; 2002 May; 13(10):1-2, 5. PubMed ID: 12492085
    [No Abstract]   [Full Text] [Related]  

  • 7. The pharmacist and adverse drug reaction reporting.
    Pearson K
    Hosp Pharm; 1982 Aug; 17(8):421-2, 427-30. PubMed ID: 10256700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse drug event reporting. Improving the low US reporting rates.
    Edlavitch SA
    Arch Intern Med; 1988 Jul; 148(7):1499-503. PubMed ID: 3382293
    [No Abstract]   [Full Text] [Related]  

  • 9. Systematic identification of drugs that cause birth defects--a new opportunity.
    Mitchell AA
    N Engl J Med; 2003 Dec; 349(26):2556-9. PubMed ID: 14695418
    [No Abstract]   [Full Text] [Related]  

  • 10. Making all clinical trials available for review: any impact on clinical decisions?
    Smith GH
    J Am Pharm Assoc (2003); 2005; 45(1):7-8. PubMed ID: 15730109
    [No Abstract]   [Full Text] [Related]  

  • 11. Food and Drug Administration's adverse drug reaction monitoring program.
    Lee B; Turner WM
    Am J Hosp Pharm; 1978 Aug; 35(8):929-32. PubMed ID: 677138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse event reporting: essential for science and public trust.
    Verma IM
    Mol Ther; 2001 Aug; 4(2):83. PubMed ID: 11482977
    [No Abstract]   [Full Text] [Related]  

  • 13. New FDA regulation to improve safety reporting in clinical trials.
    Sherman RB; Woodcock J; Norden J; Grandinetti C; Temple RJ
    N Engl J Med; 2011 Jul; 365(1):3-5. PubMed ID: 21651388
    [No Abstract]   [Full Text] [Related]  

  • 14. Standardized assessment of drug-adverse reaction associations--rationale and experience.
    Venulet J; Ciucci A; Berneker GC
    Int J Clin Pharmacol Ther Toxicol; 1980 Sep; 18(9):381-8. PubMed ID: 7450930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The black box warning.
    Abourjaily HM; Rosenberg M
    J Mass Dent Soc; 2002; 51(3):54-6. PubMed ID: 12380043
    [No Abstract]   [Full Text] [Related]  

  • 16. Making a difference.
    Nat Biotechnol; 2009 Apr; 27(4):297. PubMed ID: 19352347
    [No Abstract]   [Full Text] [Related]  

  • 17. FDA paves the way for drug law reform.
    Eichelberger BM
    Am J Hosp Pharm; 1978 Jul; 35(7):878, 882. PubMed ID: 665706
    [No Abstract]   [Full Text] [Related]  

  • 18. The safety of niacin in the US Food and Drug Administration adverse event reporting database.
    Alsheikh-Ali AA; Karas RH
    Am J Cardiol; 2008 Apr; 101(8A):9B-13B. PubMed ID: 18375244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How pharmacists can speed new drug approval through ADR reporting.
    Kennedy D
    Pharm Times; 1978 Mar; 44(3):44-8. PubMed ID: 10307082
    [No Abstract]   [Full Text] [Related]  

  • 20. Can a multidisciplinary initiative to increase adverse drug reaction reporting work?
    Perkerson KA; Quercia RA; Goldman M; Goddu G; Coleman CI
    Conn Med; 2004 May; 68(5):281-4. PubMed ID: 15171264
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.